Akari Therapeutics
AKTX
9 hedge funds and large institutions have $5.03M invested in Akari Therapeutics in 2019 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 3 closing their positions.
0% more ownership
Funds ownership: 0% → 0% (+0%)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
25% less funds holding
Funds holding: 12 → 9 (-3)
41% less capital invested
Capital invested by funds: $8.46M → $5.03M (-$3.43M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$324K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$315K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HP
Hikari Power
Tokyo,
Japan
|
-$85K |
| 2 |
VF
Virtu Financial
New York
|
-$80.5K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$77K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$74K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HP
1
Hikari Power
Tokyo,
Japan
| $2.83M | -$85K | -38 | -2% |
|
|
NMC
2
NEA Management Company
Timonium,
Maryland
| $913K | – | – | – |
|
|
VC
3
Vivo Capital
Palo Alto,
California
| $699K | – | – | – |
|
|
4
Renaissance Technologies
New York
| $273K | +$324K | +145 | +604% |
|
|
5
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $266K | +$315K | +141 | +588% |
|
|
VF
6
Virtu Financial
New York
| $22K | -$80.5K | -36 | -72% |
|
7
Parallax Volatility Advisers
San Francisco,
California
| $15K | – | – | – |
|
|
TC
8
Truvestments Capital
Sarasota,
Florida
| $8K | – | – | – |
|
9
Morgan Stanley
New York
| $2K | – | – | – |
|
|
10
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$77K | -27 | Closed |
|
|
TSS
11
Two Sigma Securities
New York
| – | -$74K | -26 | Closed |
|
|
12
UBS Group
Zurich,
Switzerland
| – | -$4K | -2 | Closed |
|
AKTX Hedge Fund Activity: Q2 2019 in Review
9 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Akari Therapeutics (AKTX) for Q2 2019, worth a combined $5.03M — down 41% from $8.46M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of AKTX and 0 opened new positions — a net loss of 3 holders — while 2 trimmed existing stakes and 2 added.
The largest buyer was Renaissance Technologies, adding an estimated $324K. The largest seller was Hikari Power, cutting an estimated $85K.
- 9 institutional investors held Akari Therapeutics (AKTX) as of Q2 2019, down from 12 in Q1 2019.
- Funds reported $5.03M of Akari Therapeutics stock for Q2 2019, down 41% quarter-over-quarter.
- 0 funds opened new Akari Therapeutics positions in Q2 2019 and 3 closed out, a net change of -3 holders.
- The largest Akari Therapeutics buyer in Q2 2019 was Renaissance Technologies, an estimated $324K added.
- The largest Akari Therapeutics seller in Q2 2019 was Hikari Power, an estimated $85K sold.
Based on aggregated 13F filings for Q2 2019.